Optiscan Imaging Ltd
Optiscan Imaging Limited is a commercial stage medical technology company.
The business
Optiscan Imaging Limited is a commercial stage medical technology company. It creates a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. It is engaged in development, manufacturing, and commercialization of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Its technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level. Its products include InVue, InForm, InVivage, ViewnVivo and InSpecta. ViewnVivo offers single-cell level live imaging, providing biological system insights and enabling users to see life connected. Developed with its patented confocal imaging technology, ViewnVivo is a miniaturized in vivo imaging device that offers single-cell 3D live microscopic imaging in the palm of your hand. InVivage is an intra-oral digital endomicroscope.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news

Optiscan Imaging Advances InForm Device with Digital Pathology Study
Optiscan Imaging advances ACL study, >80 cases imaged with InForm slide-free digital pathology, accelerating clinical validation and rollout.

Optiscan Launches US Study of InVue and InForm Imaging Devices for Head and Neck Cancer Surgeries
Optiscan kicks off US Mayo Clinic study of 35-patient InVue/InForm for head and neck cancer; real-time intraoperative imaging aims to back FDA submissions.

Optiscan Imaging Advances Head and Neck Cancer Study Ahead of Schedule
Optiscan Imaging pushes Stage 2 of head and neck cancer live-imaging study ahead of schedule, accelerating clinical validation and potential FDA submissions.

Optiscan Imaging Launches First Clinical Device into US Veterinary Market
Optiscan debuts InSpecta as its first US commercial clinical imaging device after FDA CVM submission, unlocking US sales in a $15.9B market.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.